Peptides: AOD-9604 — GH Fragment 176-191 for Lipolysis
Heffernan et al. 2001 (PMID 11713215): AOD-9604 reduced fat mass in obese mice and beta3-AR knockout mice, confirming lipolytic pathway distinct from full GH (animal study).
| Measure | Value | Unit | Notes |
|---|---|---|---|
| Evidence Grade | B | grade | AOD-9604 — human Phase 2/3 trials completed but insufficient efficacy for FDA approval; not same as no evidence |
| Sequence Position | 176–191 | amino acids | C-terminal fragment of human GH; 16 amino acid peptide designed specifically for lipolytic activity |
| IGF-1 Elevation | 0 | % change | Does not bind IGF-1 receptor; no anabolic IGF-1 effects — key distinction from full GH |
| Phase 2 Oral Dose | 1 | mg/day | Metabolic Pharmaceuticals Phase 2 trial used oral administration; off-label injectable use 250–500mcg |
| FDA IND Status | Closed | regulatory | Phase 3 did not demonstrate sufficient efficacy; development abandoned; no current NDA or IND active |
| β3-AR Pathway | Primary | mechanism | Activates β3-adrenergic receptors on adipocytes → lipolysis; inhibits lipogenesis; distinct from IGF-1 pathway |
| Common Injectable Dose | 250–500 | mcg/day | Off-label research use; no established clinically validated dose for injectable route |
What Is AOD-9604?
AOD-9604 is a synthetic peptide comprising amino acids 176 through 191 of the C-terminal region of human growth hormone — a 16-amino-acid fragment. It was engineered by researchers at Metabolic Pharmaceuticals (Australia) to isolate the lipolytic (fat-mobilizing) properties of GH from the growth-promoting, anabolic, and diabetogenic properties associated with the full molecule.
The fundamental design goal: lipolysis without IGF-1. Full recombinant HGH raises IGF-1, drives protein synthesis, causes water retention, and risks insulin resistance. AOD-9604 does none of these things because it does not bind the IGF-1 receptor. Its effects are confined to adipose tissue, where it activates β3-adrenergic receptors to stimulate fat breakdown and inhibit new fat storage.
Mechanism of Action
The proposed mechanism operates via two pathways in adipocytes:
- Lipolysis activation: β3-adrenergic receptor agonism → intracellular cAMP elevation → activation of hormone-sensitive lipase → triglyceride hydrolysis
- Lipogenesis inhibition: suppression of fat cell lipogenic enzymes, reducing new fat storage
Heffernan et al. 2001 (PMID 11713215) confirmed this pathway in an animal study comparing AOD-9604 to full HGH in obese mice and in β3-adrenergic receptor knockout mice. In the knockout model, AOD-9604’s lipolytic effect was abolished, confirming β3-AR dependence (animal study). Full HGH retained partial lipolytic activity in knockout mice, indicating it uses additional pathways.
Comparison: AOD-9604 vs Full HGH vs Semaglutide
| Characteristic | AOD-9604 | HGH (Full) | Semaglutide |
|---|---|---|---|
| Mechanism | β3-AR agonist (lipolysis) | GHR → IGF-1 + lipolysis + anabolism | GLP-1R agonist (appetite + insulin) |
| IGF-1 elevation | None | Significant (dose-dependent) | None |
| Lipolysis effect | Direct adipocyte stimulation | Indirect via GH/IGF-1 signaling | Indirect via caloric deficit |
| Anabolic effect | None | Significant (muscle, organ growth) | None |
| Evidence grade | B | A (pharmaceutical HGH) | A (multiple large RCTs) |
| FDA status | IND closed; no approval | Approved (various indications) | Approved (Ozempic, Wegovy) |
| Route | Oral (trials) / injectable (off-label) | Subcutaneous injection | Subcutaneous injection |
| Dose | 1mg/day oral (trials); 250–500mcg injectable | 0.5–2 IU/day | 0.25–2.4mg/week |
FDA Development History
Metabolic Pharmaceuticals, an Australian biotech, conducted an IND program through the early 2000s for AOD-9604 as an oral obesity treatment. Phase 2 results were encouraging — the compound appeared to reduce visceral and total fat in overweight subjects. The company advanced to Phase 3, the pivotal efficacy study required for FDA approval.
Phase 3 results did not meet the pre-specified primary endpoint with sufficient effect size. The reduction in body weight was not large enough or consistent enough to justify FDA approval in a competitive obesity treatment landscape. The development program was discontinued. There is no active IND or NDA for AOD-9604 as of 2026.
This outcome should not be conflated with “proof the compound doesn’t work.” The Phase 2/3 evidence base is more substantial than most research chemicals in this category, earning AOD-9604 a Grade B evidence rating. The failure was a regulatory determination of insufficient clinical benefit, not a finding of harm or complete inefficacy.
Legal and Regulatory Status
| Jurisdiction | Status | Schedule | Notes |
|---|---|---|---|
| USA | Research chemical | Unscheduled | FDA IND closed; no approved pharmaceutical; not a scheduled substance |
| UK | Not scheduled | — | No licensed product; importation as research chemical |
| Australia | Schedule 4 (TGA) | Prescription required | Originally developed by Australian company; TGA scheduling applies |
| Canada | Gray market | Not scheduled | No Health Canada approval; importation technically unregulated |
| EU | Unscheduled | — | Not EMA-approved; no EU pharmaceutical product |
AOD-9604 is not currently on the WADA prohibited list as a named substance. Athletes should verify current WADA guidance, as the prohibited list evolves and general categories (e.g., GH fragment analogues) may apply.
Current Research Perspective
The injectable off-label use of AOD-9604 at 250–500mcg/day is common in research communities, despite the fact that the clinical trials used oral dosing. The injectable route was not the studied route, meaning there is no direct clinical data for injectable pharmacokinetics or efficacy. Off-label injectable use is extrapolation from a different route of administration.
Stier et al. 2013 (PMID 23234372) confirmed that AOD-9604 is well-tolerated in humans with no concerning changes in glucose, insulin, or cardiovascular parameters — which is a meaningful distinction from full HGH, but does not validate efficacy for any specific outcome.
Related Pages
Sources
- Heffernan M et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice. Endocrinology. 2001;142(12):5182-9. PMID 11713215 (animal study)
- Stier H et al. Safety and tolerability of AOD-9604 in healthy volunteers. J Endocrinol Invest. 2013;36(4):249-55. PMID 23234372
Frequently Asked Questions
Does AOD-9604 raise IGF-1 levels?
No. AOD-9604 (GH fragment 176-191) does not bind the IGF-1 receptor and does not stimulate hepatic IGF-1 production. This is the core design intention: isolate the fat-mobilizing activity of growth hormone without triggering the anabolic and potentially proliferative effects associated with IGF-1 elevation. This distinguishes AOD-9604 fundamentally from full recombinant HGH.
Why did AOD-9604 fail FDA approval?
Metabolic Pharmaceuticals' Phase 3 trial for obesity treatment did not demonstrate a statistically significant and clinically meaningful reduction in body weight compared to placebo. Phase 2 data had shown promising signals in visceral fat reduction, but the larger Phase 3 could not replicate these findings with sufficient effect size to meet FDA approval thresholds. The compound's development was subsequently abandoned.
What is the difference between AOD-9604 and semaglutide for fat loss?
They act through completely different mechanisms. Semaglutide activates GLP-1 receptors in the hypothalamus and gut to suppress appetite, leading to reduced caloric intake and ~14.9% body weight loss (STEP 1 trial, PMID 33567185). AOD-9604 acts peripherally on β3-adrenergic receptors in fat cells to stimulate lipolysis directly, without significant appetite suppression. Semaglutide has Grade A evidence from large RCTs; AOD-9604 has Grade B evidence from trials that did not achieve approval-level efficacy.
Is AOD-9604 safe based on available human data?
Stier et al. 2013 (PMID 23234372) reported that AOD-9604 was well-tolerated in healthy volunteers across a range of doses, with no serious adverse events and no significant changes in glucose or insulin parameters — a notable contrast to full HGH. The safety profile appears favorable, but the sample sizes were small, and the compound lacks the long-term safety database of approved pharmaceuticals.